U.S. Biotech Stock News

Earlier this week, Exponent reported revenues that narrowly exceeded analyst expectations but issued revenue guidance for the coming quarter that landed just below forecasts. This cautious outlook, and the company’s persistently high price-to-earnings ratio despite tepid earnings growth, has drawn attention to concerns about the sustainability of Exponent’s valuation given current performance trends. We'll explore how Exponent's softer revenue guidance and muted growth outlook may reshape...

If you are wrestling with what to do about W.W. Grainger stock right now, you are not alone. Investors have watched Grainger’s shares move sideways and then downward lately, with the price dropping slightly over the past month and a pullback of over 7% in the last 90 days. Yet, when viewed from a longer-term perspective, the story brightens. The stock has delivered a solid 2.6% total return over the past year and has more than doubled over five years. Clearly, this is not a sleepy industrial...

Ares Management (ARES) has caught investor attention again this week, though not for a specific breaking event or dramatic headline. Instead, the stock’s recent moves have many asking themselves whether this quiet period is actually a signal. Perhaps the market is just taking a breather before its next decisive step. For long-term shareholders and those watching from the sidelines, it raises that ever-present question: are we missing something right in front of us? If you zoom out, Ares...

Fluence Energy, Inc. ( NASDAQ:FLNC ) shares have retraced a considerable 33% in the last month, reversing a fair amount...

The recent surge in Charles Schwab (SCHW) shares might have caught your eye, especially if you’re wondering whether it’s a fleeting bounce or something more. There hasn’t been a single headline-grabbing event lighting up the news feed. However, the quiet momentum in Schwab’s stock has fueled plenty of back-and-forth among investors. It’s the kind of move that doesn’t demand urgency but definitely calls for a closer look at what might be unfolding beneath the surface. Stepping back, Schwab’s...

Recently, SLM reported that its short percent of float increased by 18.42% since the previous update, with 8.78 million shares now sold short, representing 4.95% of its available trading shares and an average of 3.84 days to cover these positions based on trading volume. This shift suggests traders are increasingly expecting downward movement in SLM's share price, which can influence investor sentiment and trading behavior. We'll explore how the recent rise in short interest could influence...

If you have been watching Elevance Health (ELV) lately, the stock’s recent slide might pique your curiosity. Shares have drifted lower, closing just under $310, and while there is no single headline driving this move, the change in direction comes as investors weigh the company’s longer-term prospects against current performance. Even with steady revenue and net income growth in the past year, the market’s sentiment appears to be shifting. Looking beyond this month’s nearly 10% gain, Elevance...

Key Insights Significantly high institutional ownership implies AppFolio's stock price is sensitive to their trading...

If you are sitting on the fence about what to do with Parker-Hannifin stock, you are not alone. After a string of strong performances over the past year, many investors are trying to decide whether PH still has room to run, or if it is time to take some profits off the table. The past 12 months have treated shareholders well, with a total return of 26.1%. Even more impressive, the stock has more than doubled over the last three years, rewarding long-term holders who believed in the company's...

Thinking about what to do with Williams-Sonoma stock? You are not alone. Even seasoned investors have been keeping a closer eye on WSM, especially after the impressive run over the last year. The stock’s recent performance tells quite the story. It is up roughly 53% over the past twelve months and has more than tripled over the past five years. That kind of growth is hard to ignore, and it has left many wondering whether Williams-Sonoma is still a buy or if it is time to lock in gains. Over...

Akso Health Group recently announced its full year financial results for the period ended March 31, 2025, reporting sales of US$14.78 million and a net loss of US$134.98 million, alongside a basic and diluted loss per share of US$0.48. In addition, the company’s auditor expressed doubt about Akso Health Group’s ability to continue as a going concern in its latest annual filing, highlighting financial sustainability risks despite the growth in reported revenue. We’ll examine what the...

If you are weighing whether to jump into Royalty Pharma or considering if it is time to take some profits, you are not alone. This stock has become a topic of lively debate, especially as its recent run has caught the attention of both cautious and opportunistic investors. Over the past year, Royalty Pharma has delivered a total return of over 34%. What really stands out is its nearly 41% surge year-to-date. While its five-year numbers are barely in the red, the short-term momentum is...

Thinking about what to do with Boston Scientific stock? You are not alone. With the company’s shares up an impressive 17.7% year-to-date and a remarkable 32.2% over the past year, it is no wonder many investors are wondering if there is still room to grow, or if it is time to take some profits off the table. The stock’s five-year run, delivering an eye-catching 157.9% total return, speaks to strong momentum. However, this also raises questions about whether that growth is justified or coming...

Key Insights The considerable ownership by individual investors in Richtech Robotics indicates that they collectively...

Deciding what to do with your Zoom Communications stock these days feels a little like trying to tune in to the right frequency, with so many signals flying around. After the wild swings of recent years, you might be wondering if now is the right time to buy, hold, or even walk away. The stock price, lately hovering around $73, has been on a bit of a roller coaster, down just over 10% year-to-date, but up about 7.5% in the past year. That back-and-forth movement says a lot about shifting...

Some Eton Pharmaceuticals, Inc. ( NASDAQ:ETON ) shareholders may be a little concerned to see that the CFO, Treasurer...

We wouldn't blame Ralph Lauren Corporation ( NYSE:RL ) shareholders if they were a little worried about the fact that...

If you are watching Abbott Laboratories (ABT) this week, the stock’s recent run-up might have you wondering if there is a new story unfolding. There is no single headline or corporate event moving shares, but the persistent climb in its price is starting to draw more investor attention. When a stock like Abbott moves higher without a big, clear-cut catalyst, it often prompts investors to dig deeper into what is really driving sentiment, especially with economic uncertainty still present in...

With the business potentially at an important milestone, we thought we'd take a closer look at Achieve Life Sciences...

Investors may wish to note that the Executive VP & CFO of CS Disco, Inc. , Michael Lafair, recently netted US$72k from...

Thinking about what to do with Plug Power stock? You are not alone. With eye-popping short-term moves and nerve-wracking long-term slides, Plug Power’s stock has kept traders and investors on their toes. Just this past quarter, shares nearly doubled, climbing 97%, which stands out against the rougher ride over the last few years. With the price currently at $1.54 and still discounted about 28% compared to analyst targets, it is clear that expectations are shifting rapidly in both...

If you have ever found yourself staring at Conagra Brands’ stock chart and debating your next move, you are not alone. The consumer staples giant, trading under the ticker symbol CAG, has certainly given investors a lot to think about lately. After a choppy year, the stock recently closed at $19.30, down just under 1% over the last month and more than 30% year-to-date. Longer-term performance tells a similar story, with the one-year total return sitting at -33% and five-year total return near...

If you have been eyeing Kyndryl Holdings and wondering whether now is the right moment to buy, hold, or even reconsider your strategy, you are not alone. The company's stock has seen some dramatic swings lately, stirring up plenty of debate among investors trying to make sense of its momentum. Over the past year, Kyndryl’s stock is up more than 30%, which is impressive, especially when compared to some of its peers. However, shorter-term moves have been more volatile, with a 1-day gain of...

Monolithic Power Systems (MPWR) has seen a fresh wave of attention after its stock dipped slightly, closing 0.7% lower yesterday. While there is no headline-making news or AI announcement fueling the move, any quick turn in share price tends to stir up questions, especially with how dynamic the semiconductor sector has felt lately. For investors on the fence, even modest drops in a quality name like this can feel like either a warning sign or a window of opportunity. Taking a broader view,...